Physician profile
Rhoads E Stevens
NPI 1194812503
$4,202.91
in general payments reported to CMS, 2019-2025
18 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $157 · 2021: $46.85 · 2022: $761 · 2023: $661 · 2024: $1,030 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.62 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $734.11 | 2022-2025 | Oxervate |
| Alcon Vision LLC | $722.55 | 2022-2025 | Hydrus Microstent, Clareon, Unity |
| Regeneron Healthcare Solutions, INC. | $480.76 | 2019-2025 | Eylea Hd, Eylea |
| Amgen INC. | $276.44 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $241.08 | 2024-2025 | Syfovre |
| Horizon Therapeutics Plc | $232.94 | 2021-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $161.21 | 2024 | Acthar |
| Eyevance Pharmaceuticals LLC | $155.42 | 2019 | |
| Genentech USA, INC. | $141.50 | 2022 | |
| Allergan, INC. | $139.26 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $134.66 | 2023-2024 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $133.86 | 2025 | Xdemvy |
| Abbvie INC. | $125.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $124.99 | 2025 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $120.82 | 2024 | Tyrvaya |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $119.56 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Johnson & Johnson Surgical Vision, INC. | $96.42 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.33 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhoads Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.